Relmada Therapeutics Q3 2023 Earnings Report $0.29 +0.01 (+4.98%) As of 03/7/2025 04:00 PM Eastern Earnings HistoryForecast Relmada Therapeutics EPS ResultsActual EPS-$0.73Consensus EPS -$0.95Beat/MissBeat by +$0.22One Year Ago EPSN/ARelmada Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARelmada Therapeutics Announcement DetailsQuarterQ3 2023Date11/8/2023TimeN/AConference Call ResourcesPress ReleaseRLMD Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Relmada Therapeutics Earnings HeadlinesRelmada acquires new Tourette syndrome treatment assetFebruary 6, 2025 | msn.comPsychedelic: Relmada acquires neurosteroid from AsarinaFebruary 6, 2025 | markets.businessinsider.com“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…March 9, 2025 | True Market Insiders (Ad)Relmada Therapeutics acquires Sepranolone from Asarina PharmaFebruary 6, 2025 | markets.businessinsider.comRelmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma ABFebruary 6, 2025 | globenewswire.comRLMD stock touches 52-week low at $0.34 amid sharp annual declineFebruary 3, 2025 | msn.comSee More Relmada Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Relmada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relmada Therapeutics and other key companies, straight to your email. Email Address About Relmada TherapeuticsRelmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.View Relmada Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
